Treatments and compositions for reducing atherosclerotic plaques

By delivering cholesterol-degrading proteins via lipid nanoparticles that target hepatocytes, this method addresses the problem that existing technologies cannot effectively shrink atherosclerotic plaques, achieving significant plaque regression and improved cardiovascular function.

CN123076394APending Publication Date: 2026-11-10REPAIR BIOTECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580027581.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-25
Filing Date
2025-03-25
Publication Date
2026-11-10

Smart Images

  • Figure CN123076394A_ABST
    Figure CN123076394A_ABST
Patent Text Reader

Abstract

This article discloses treatment methods and compositions for treating atherosclerosis and regressing distal atherosclerotic plaques, wherein the compositions are administered to subjects and targeted to the liver.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application is based on 35 USC 119(e) claims priority to U.S. Provisional Patent Application No. 63 / 569,437, filed March 25, 2024, entitled “ATHEROSCLEROTIC PLAQUE REDUCTION TREATMENTS AND COMPOSITIONS,” which is incorporated herein by reference in its entirety.

[0003] sequence list

[0004] This application contains a sequence list, which has been electronically submitted in XML format and is incorporated herein by reference in its entirety. The XML file, created on March 25, 2025, is named P318597WO01.xml and is 20,589 bytes in size. Background Technology

[0005] Atherosclerosis is a chronic, maladaptive inflammatory response triggered by the retention of cholesterol-rich low-density lipoprotein (LDL-C) within the arterial walls. The accumulation of these lipoproteins leads to the formation of atherosclerotic plaques on the arterial walls. Plaque rupture and displacement can cause ischemic stroke and myocardial infarction, making it one of the leading causes of death in the United States.

[0006] Circulating monocytes / macrophages enter the arterial wall, take up excess LDL-C, and transfer the cholesterol to high-density lipoprotein (HDL-C), attempting to prevent further cholesterol accumulation by returning the cholesterol to the circulation and eventually sending it to the liver for excretion. This process is called cholesterol reverse transport.

[0007] Currently, medical treatment for atherosclerosis mainly focuses on altering certain aspects of normal lipoprotein metabolism to slow the accumulation of lipoproteins (primarily LDL) in blood vessels. For example, statins target and weaken de novo cholesterol synthesis, while PCSK9 inhibitors increase the availability of LDL receptors on cell surfaces, thereby increasing the uptake of circulating LDL-C.

[0008] Adverse cardiovascular events and mortality depend on the burden of atherosclerotic plaques. Human studies have shown that the level of plaque present in an individual corresponds to 67-100% of the risk of cardiovascular disease (CVD). Therefore, plaque regression is associated with a reduction in CVD risk. For example, a 1% reduction in atherosclerotic volume is associated with approximately a 20% reduction in major cardiovascular events.

[0009] While statins and PCSK9 inhibitors can slow the growth of atherosclerotic plaques by lowering circulating LDL-C levels, they are not effective at shrinking the size of existing plaques. Therefore, these treatments only slightly reduce cardiovascular disease mortality in humans (approximately 15%).

[0010] Therefore, the mortality rate associated with atherosclerotic CVD remains high, making it imperative to develop therapeutic compositions and methods that can achieve meaningful regression of atherosclerotic markers such as plaque size. Summary of the Invention

[0011] This document discloses a method and system for reducing at least one measurable aspect of atherosclerotic plaques in a subject, comprising: identifying at least one atherosclerotic plaque in the subject by means of a measurable aspect having a first value; administering a composition comprising: at least one cholesterol-degrading protein, and at least one molecule or compound configured to bind to a hepatocyte surface protein; expressing the at least one cholesterol-degrading protein in hepatocytes; and measuring the measurable aspect to determine a second value, wherein the difference between the first value and the second value is greater than 5%. In many embodiments, the subject may have hypercholesterolemia, familial hypercholesterolemia, heterozygous familial hypercholesterolemia, or homozygous familial hypercholesterolemia, and the measurable aspect may be selected from area, volume, and collagen content. In some embodiments, the method further includes the step of administering a statin or a PCSK9 inhibitor to the subject. Attached Figure Description

[0012] Figure 1 The following are schematic diagrams: A) Hepatic lobule, showing the central vein, portal vein triad (hepatic artery, hepatic vein, and bile duct), and targeted hepatocytes; B) CDP1 mRNA encapsulated in LNPs, which have an average diameter of 80 nm and are surface-coated with polyethylene glycol-based lipids (PEG-lipids) and N-acetylgalactosamine (GalNAc) lipids with low surface charge; C) The compact size of the LNPs allows them to pass through hepatic sinusoidal windows, which are typically 100-200 nm in diameter, while the surface GalNAc facilitates their binding and uptake via ASGPR. This allows the ionizable lipids of the LNPs to release CDP1 mRNA into the hepatocyte cytoplasm, where it can be translated by ribosomes.

[0013] Figure 2 : Kinetics of CDP1 expression after a single LNP-mRNA treatment. Total protein extracted from the right lobe of mouse liver was separated by SDS-PAGE, and the expression level of CDP1 relative to the housekeeping protein α-tubulin was quantified by Western blot. The half-life of CDP1 expression was assessed to be approximately 37.5 hours.

[0014] Figure 3 shows the results of 6 weeks of LNP-CDP1 mRNA treatment, which significantly reduced plaque lipids in the aortic root without lowering serum LDL-cholesterol. (A) Mice treated with CDP1 (G3-LNP-CDP1 mRNA) showed a significant 19% reduction in aortic root plaque lipids compared to the control (G1-LNP-empty) (P=0.05). Atorvastatin treatment did not induce a significant reduction. The reduction in plaque lipids can stabilize unstable plaques and reduce the risk of plaque rupture and cardiovascular events. (B) Atorvastatin treatment rapidly and significantly lowered serum LDL-cholesterol, while LNP-CDP1 mRNA treatment had no effect on serum LDL-cholesterol. However, LNP-CDP1 mRNA treatment produced profound and significant changes in the plaque environment, while atorvastatin did not.

[0015] Figure 4 CDP1 treatment showed a significant increase ApoE knockout Collagen content in plaques at the root of the aorta in mice. Cholesterol-rich plaques are unstable, and acute coronary events (such as myocardial infarction) are often caused by the rupture of unstable atherosclerotic plaques. Collagen plays a crucial role in determining plaque stability. LNP-CDP1 mRNA treatment significantly increased plaque collagen content in addition to significantly reducing plaque lipid content (P<0.05 compared to the mediator), while atorvastatin alone had no effect on collagen content. LNP-CDP1 mRNA monotherapy and combination therapy (atorvastatin + LNP-CDP1 mRNA) increased collagen content to similar degrees, indicating that this response is CDP-specifically mediated.

[0016] Figure 5 CDP1 treatment has shown to significantly reduce serum free cholesterol and triglycerides. CDP1 is expected to reduce circulating free cholesterol because intracellular free cholesterol is a target of CDP1. The reduction in serum triglycerides is generally considered beneficial because there is evidence linking elevated triglyceride levels to atherosclerotic heart disease.

[0017] Figure 6 CDP1 treatment significantly increased serum IL-10 levels. IL-10 possesses potent anti-inflammatory properties in macrophages and T cells. It regulates numerous cellular processes that interfere with the formation and stability of atherosclerotic plaques. Increased expression may contribute to the observed effects of CDP1 treatment on plaques.

[0018] Figure 7CDP1 treatment showed a significant increase in SRA1 expression in spleen tissue. The spleen contains monocytes that enter the circulation and migrate to plaque and endothelial injury areas, where they transform into macrophages. Increased SRA1 expression is known to have beneficial effects on macrophage function and reduce inflammation.

[0019] Figure 8 CDP1 treatment showed that it reduced the presence of serum lipids. LDLR knockout mice exhibited dyslipidemia and turbid serum. In this group of samples, serum lipid levels were significantly reduced over the time interval following a single LNP-CDP1 mRNA injection, up to a time point of 96 hours.

[0020] Figure 9 CDP1 treatment significantly reduced serum triglycerides. Although serum triglyceride levels in LDLR knockout mice were much higher than... ApoE knockout In mice, however, the relative effect of CDP1 treatment on serum triglyceride levels in LDLR knockout mice was different from that on... ApoE knockout The relative effects were similar in mice. Decreased serum triglycerides are generally considered beneficial because there is evidence linking elevated triglyceride levels to atherosclerotic heart disease.

[0021] Figure 10 CDP1 treatment significantly reduced serum total cholesterol. CDP treatment also reduced serum total cholesterol in LDLR knockout mice.

[0022] Figure 11 CDP1 treatment showed that it could rapidly and significantly reduce serum alanine transaminase (ALT). Elevated serum ALT is characteristic of liver disease, while decreased serum ALT indicates reduced hepatic cell stress and cell death.

[0023] Figure 12 CDP1 treatment showed a significant reduction in total cholesterol levels in liver tissue. Excess cholesterol in liver tissue is pathological, forcing cells to carry excessive amounts of toxic intracellular free cholesterol, leading to functional impairment.

[0024] Figure 13 CDP1 treatment in LDLR mice showed that plaque regression was induced.

[0025] Figure 14 Low-dose CDP1 treatment in LDLR mice showed that plaque regression could be induced.

[0026] Figure 15 The results showed that all groups receiving REP-0003 / CDP1 treatment were significantly better than those receiving mediator therapy, indicating improved cardiovascular function. Detailed Implementation

[0027] This article discloses methods and systems for systemic treatment of atherosclerosis by targeting intracellular cholesterol metabolism in hepatocytes. In many embodiments, the disclosed treatment methods can regress atherosclerotic plaques in distal hepatic sites, such as plaques in or near the aorta, and / or increase the collagen content of the plaques. In many embodiments, the disclosed therapeutic methods and compositions also affect serum levels of various biomarkers, including cholesterol, triglycerides, cytokines, and transcriptional cofactors.

[0028] Surprisingly, despite targeting liver tissue, the therapeutic methods and compositions disclosed by the applicant can still produce rapid and measurable systemic beneficial effects. In some embodiments, these surprising results include the regression of atherosclerotic plaques without change in serum lipoprotein concentration levels (e.g., low-density and very low-density lipoproteins).

[0029] This document discloses therapeutic methods and compositions targeting liver cells (e.g., hepatocytes). In many embodiments, the compositions comprise lipid nanoparticles (LNPs). In many embodiments, the size of the LNPs can be designed to easily pass through hepatic sinusoidal fenestrations, typically with a diameter between 100 and 200 nm. In many embodiments, the diameter of the LNPs is approximately 80 nm. The disclosed LNPs may contain one or more targeting molecules that can help target liver cells. In various embodiments, the targeting molecule may comprise N-acetylgalactosamine (GalNAc). GalNAc may help target LNPs to liver cells by binding to the asialic acid glycoprotein receptor (ASGPR) on the surface of hepatocytes. ASGPR is expressed only by hepatocytes and some circulating monocytes. However, because monocytes are circulating cells, they take up very little GalNAc-targeted LNPs. Efficient endocytosis and recycling (approximately 15 minutes) make ASGPR an ideal protein for liver-specific therapies. LNPs that introduce GalNAc-targeted ASGPR can rapidly bind to and be internalized by hepatocytes. LNP cargoes, such as sequences encoding cholesterol degradation proteins (CDPs), then enter the cytoplasm, where they can be translated by ribosomes. Figure 1 The illustration shows one embodiment of the disclosed therapeutic compound targeting liver cells.

[0030] The disclosed therapeutic compositions and methods can facilitate the conversion of cholesterol into another compound. In various embodiments, the disclosed proteins and enzymes can aid in the conversion of cholesterol into pregnenolone. Studies have shown that pregnenolone has anti-inflammatory effects on relevant cell populations, such as macrophages. In macrophages, pregnenolone has been shown to promote the ubiquitination and degradation of the Toll-like receptor (TLR)2 / 4 adaptor proteins TLRAP and TLR2 in both macrophages and microglia. This leads to a reduction in the secretion of pro-inflammatory cytokines TNF-α and IL-6, which would otherwise be enhanced through TLR2 and TLR4 signaling.

[0031] The in vivo experimental results disclosed in this paper demonstrate that the disclosed therapeutic compounds and treatment methods (including targeting hepatocytes with lipid nanoparticles containing sequences encoding cholesterol degradation proteins) can significantly and rapidly reduce lipids in atherosclerotic plaques in mice diagnosed with atherosclerosis and affect other biomarkers associated with atherosclerosis.

[0032] Surprisingly, research in this invention has shown that the disclosed compositions and methods are effective in mice with hypercholesterolemia whose liver cells lack functional apolipoprotein E (involved in lipoprotein formation) and low-density lipoprotein receptors. Furthermore, the extent and speed of plaque regression far exceed what is achievable with current standard care. Surprisingly, although these therapies target the liver, plaque areas along or near the aortic pathway are significantly affected by the disclosed treatments.

[0033] Currently, standard care consists of interventions using compounds that target serum LDL cholesterol, such as statins and PCSK9 inhibitors, which have little effect on the size of existing plaques.

[0034] Therapeutic Composition

[0035] This document discloses various therapeutic compositions for treating diseases or disorders associated with elevated levels of cholesterol and / or triglycerides in serum and tissues. In many embodiments, the therapeutic compositions deliver one or more active ingredients to a specific cell type, such as hepatocytes. In many embodiments, the disclosed compositions comprise lipid nanoparticles (LNPs) surrounding the active ingredient. In many embodiments, the disclosed LNPs may comprise at least one molecule with affinity for a liver-specific surface protein (e.g., ASPGR). In some embodiments, the disclosed compositions may be referred to as CDP, LNP-mRNA, LNP-CDP, or REP-0003.

[0036] Affinity can refer to the affinity of one molecule for another—such as a ligand and its receptor, for example, a surface receptor. In some embodiments, affinity can manifest as relative binding—for example, two different ligands competing for the same receptor. In this case, the disclosed therapeutic composition exhibits affinity for hepatocytes, particularly for the ASPG receptor on hepatocytes.

[0037] Active ingredients

[0038] As used herein, the term "active ingredient" or "active pharmaceutical ingredient" refers to a drug, compound, substance, composition, or mixture thereof that provides a pharmacological effect (typically a beneficial or ameliorative effect). In various embodiments, the active ingredient is a nucleic acid, such as a deoxyribonucleotide or ribonucleotide. In many embodiments, the active ingredient is a polynucleotide, such as mRNA. In many embodiments, the active ingredient may encode a fusion protein, and in most embodiments, the fusion protein comprises cytochrome P450.

[0039] improve

[0040] As used herein, improvement refers to any improvement in the disease state of a patient with a disease (e.g., hypercholesterolemia or atherosclerosis) by administering one or more therapeutic compositions or active ingredients to a patient or subject in need according to this disclosure. Such improvement can be considered as a slowing or cessation of disease progression, or the disappearance of a particular aspect or symptom, a reduction in the frequency, duration, and / or severity of any symptom, and / or an increase in the frequency or duration of asymptomatic periods of the disease, or prevention of injury or disability caused by the disease.

[0041] Co-application

[0042] Co-administration refers to the administration of two (or more) therapeutic active ingredients or drugs. In some embodiments, co-administration may be simultaneous, for example, combining the active ingredients in intravenous delivery. In other embodiments, co-administration may be sequential (i.e., one after another), for example, infusing the first active ingredient first, followed by the second active ingredient. In some embodiments, co-administration may involve combining two (or more) drugs or active ingredients into the same syringe or intravenous infusion bag, or adding the second drug to an intravenous infusion bag containing the first drug prior to co-administration. In other embodiments, one drug may be delivered intravenously, and the other drug may be delivered orally or otherwise. In some embodiments, the administration regimen for delivering the co-administered drug (e.g., a statin) may differ from the administration regimen for, for example, the therapeutic compositions disclosed in this invention.

[0043] statins

[0044] Statins are cholesterol-lowering drugs that specifically inhibit HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase; HMGCR) and help treat dyslipidemia. HMGCR is the rate-limiting enzyme in the mevalonate pathway, which produces cholesterol and other isoprene compounds. It catalyzes the conversion of HMG-CoA to mevalonate, a crucial step in cholesterol synthesis. The first approved HMGCR inhibitor, or statin, was lovastatin, a natural fungus-derived drug, approved in 1987 and initially named mevinolin; followed by another naturally occurring statin, simvastatin (Zocor; 1998)—after which synthetic statins emerged, including pravastatin (Pravachol; 1991), fluvastatin (Lescolin; 1994), atorvastatin (Lipitor; 1997), cerivastatin (Baycol; 1998), and rosuvastatin (Crestor; 2003).

[0045] Gene therapy

[0046] This document discloses therapeutic methods and compositions for delivering one or more cholesterol-related proteins or enzymes into cells. In many embodiments, the proteins and enzymes can degrade or break down intracellular cholesterol. In many embodiments, the disclosed methods and compositions can help induce rapid and significant regression and / or stabilization of atherosclerotic plaques.

[0047] The disclosed cholesterol-related proteins and enzymes can catalyze a chemical reaction involving at least one cholesterol component. In many embodiments, the disclosed proteins and enzymes can be used to convert cholesterol into another compound, for example, by catalyzing the removal of cholesterol side chains. In many embodiments, the disclosed proteins and enzymes may include one or more of the following: cytochrome P450 (e.g., but not limited to cholesterol P450 side chain lyase, CYP11A, CYP27A, CYP8, CYP7, CYP3), P450 oxidoreductase / POR, cytochrome b5, ferredoxin reductase (FdxR; AdxR / adrenocortical ferredoxin reductase), and ferredoxin (Fdx; Adx / adrenocortical ferredoxin). In many embodiments, the protein or enzyme is a fusion, such as (P450-FdxR-Fdx), which can catalyze the conversion of cholesterol into pregnenolone. The terms CYP and Cyp as used herein can refer to a gene, coding sequence, amino acid sequence, and / or protein.

[0048] Humans possess two types of cytochrome P450 enzymes. Type I is found in mitochondria (i.e., Cyp11A and Cyp27A), while type II is associated with microsomal portions (e.g., the endoplasmic reticulum). The electron transport chains of type II cytochromes (e.g., Cyp3A, Cyp7A, and Cyp8A) differ slightly from those of type I cytochromes. In some embodiments, the disclosed fusion proteins may comprise type II P450. These type II fusion proteins may include one or two additional protein modules. In some embodiments, the type II fusion protein may comprise an example Cyp7A and a membrane-bound P450 oxidoreductase (POR), and optionally a cytochrome b protein, such as cytochrome b5.

[0049] P450 and P450 fusion protein

[0050] The disclosed side-chain lyases may include a variety of cytochrome proteins. In many embodiments, the cytochrome P450 protein may be selected from two-component, three-component, mitochondrial, and microsomal systems.

[0051] Various P450 proteins can be used in the disclosed compositions, methods, and systems. In various embodiments, the P450 isotype can be selected from CYP3, CYP3A, CYP7, CYP7A (NM_000780), CYP8, CYP8A, CYP11, CYP11A, CYP27, CYP27A (NM_000784.4). In many embodiments, the P450 isotype can be expressed as a fusion with FDXR / ADXR, FDX / ADX, cytochrome b5 (Cyb5A; NM_148923), and / or P450 oxidoreductase (POR; NM_001367562.3).

[0052] Various type I cytochrome P450s can be used in the disclosed fusion proteins. In some embodiments, the type I cytochrome P450 may be selected from Cyp11 and Cyp27. Cyp27A has a much higher affinity for cholesterol than Cyp11A. The km value of Cyp27A (i.e., the cholesterol concentration required to reach half of Vmax) is approximately 5-25 μM, for example, about 20 µM. The km value of Cyp11A for cholesterol may be greater than that of Cyp27A, for example, about 50 µM or higher. Furthermore, the regulation of Cyp27A may be less stringent than that of Cyp11A, and the mRNA and protein of Cyp11A may become unstable / turnover rapidly. The applicant speculates that, in some embodiments, the Cyp27A fusion protein expressed in the liver (i.e., CDP2) may be equivalent to or more effective than CDP1 in degrading excess cholesterol. Data show that Cyp27 knockout mice lose the expression of Cyp27a in all tissues (not just the liver). These Cyp knockout mice showed an approximately 5-10 fold increase in the expression of CYP7A1, CYP3A, and CYP8B1 in their livers—CYPs promote the breakdown and removal of cholesterol by converting it into bile acids.

[0053] The disclosed fusion protein may be referred to as a CDP, such as CDP1 or CDP2. In many embodiments, CDP / CDP1 / CDP11 may refer to a fusion of Cyp11A-FDXR-FDX1, while CDP2 / CDP27 may refer to a fusion of Cyp27A-FDXR-FDX1. Like CDP11, CDP27 may be expressed on the matrix-facing side of the inner mitochondrial membrane and may significantly reduce free cholesterol by metabolizing bile salt precursors. CDP may also refer to a fusion protein containing type 2 cytochrome.

[0054]

[0055] CDP1 can encode a nucleic acid with the sequence SEQ ID NO: 2. Those skilled in the art will understand that such coding sequences can be significantly altered without changing the sequence of the encoded protein, and / or produce a protein that is at least 80% identical to the protein encoded by such coding sequences.

[0056]

[0057] The disclosed CDP2 / CDP27 fusion protein can encode a nucleic acid with the sequence SEQ ID NO: 4. Those skilled in the art will understand that such coding sequences can be significantly altered without changing the sequence of the encoded protein, and / or produce proteins that are at least 80% identical to those encoded by such coding sequences.

[0058] In many embodiments, the disclosed fusion protein may contain CYP7 and have MMT-like properties. TSLIWGIAIAAC CCLWLILGI RRRQTGEPPLENGLIPYLGCALQFGANPLEFLRANQRKHGHVFTCKLMGKYVHFITNPLSYHKVLCHGKYFDWKKFHFATSAKAFGHRSIDPMDGNTTENINDTFIKTLQGHALNSLTESMMENLQ RIMRPPVSSNSKTAAWVTEGMYSFCYRVMFEAGYLTIFGRDLTRRDTQKAHILNNLDNFKQFDKVFPALVAGLPIHMFRTAHNAREKLAESLRHENLQKRESISELISLRMFLNDTLSTFDDLEKAK THLVVLWASQANTIPATFWSLFQMIRNPEAMKAATEEVKRTLENAGQKVSLEGNPICLSQAELNDLPVLDSIIKESLRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIYPD PLTFKYDRYLDENGKTKTTFYCNGLKLKYYYMPFGSGATICPGRLFAIHEIKQFLILMLSYFELELIEGQAKCPPLDQSRAGLGILPPLNDIEFKYKFKHLTDGTSMGDSHVDTSSTVSEAVAEEVS LFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWSTDGASMAEQSDEAVKYYTLEEIQKHNHSKSTWLILHHKVYDLTKFLEEHPGGEEVLREQAGGDATENFEDVGHSTDAREMSKTFIIGELHPDDRPKLNKPPETLITTIDSSSS WWTNWVIP AISAVAVALMYRLYM AED (SEQ ID NO: 5) an amino acid sequence that is at least 80% identical (note that connecting residues are depicted in bold, transmembrane residues are underline(Description). In many embodiments, the identity may be greater than about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and less than 100%, 99%, 98%, 97%, 96%, 95%, 93%, 94%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, or 81%. In some embodiments, the removal or mutation of transmembrane residues may help enable the fusion protein to work synergistically—for example, the first 27 residues of the POR protein may be deleted and / or the linker sequence may be extended to increase the degree of freedom / flexibility of the individual protein and / or improve the overall structure of the fusion protein.

[0059] The disclosed CYP7-containing fusion protein encodes a nucleic acid with the sequence SEQ ID NO: 6. Those skilled in the art will understand that such coding sequences can be significantly altered without changing the sequence of the encoded protein, and / or produce proteins that are at least 80% identical to those encoded by such coding sequences.

[0060] ferroreductase / FDXR

[0061] Also known as adrenocortical feroxonin / ADXR reductase, it is part of the mitochondrial P450 enzyme system. Specifically, it functions as the first electron transport protein, with its coenzyme FAD receiving two electrons from NADPH and transferring them to feroxonin / adrenocortical feroxonin.

[0062] ferricyanide / FDX

[0063] Also known as adrenocortical ferrugin / ADX, its function is to transfer electrons between ADXR and P450. FDX is an iron-sulfur protein that can accept / carry / transfer single electrons. Ferroretin gains electrons from ferrugin reductase to reduce cytochrome P450.

[0064] Cytochrome P450 reductase (POR)

[0065] Cytochrome P450 reductase is a membrane-bound enzyme that can transfer electrons to cytochrome P450 in the endoplasmic reticulum, such as cytochrome P450 type 2.

[0066] Cytochrome b

[0067] Targeted delivery of gene therapy

[0068] The disclosed therapeutic compositions can target specific tissues and / or contents expressed only in specific tissues. In most embodiments, the therapeutic composition targets and is expressed in liver tissue. In many embodiments, the therapeutic composition targets and is expressed in liver cells, such as hepatocytes.

[0069] In some embodiments, the therapeutic composition may comprise nanoparticles or liposomes and one or more nucleic acid-coding sequences, such as mRNA. In many embodiments, lipid nanoparticles (LNPs) can be used to deliver polynucleotides, such as mRNA, or other therapeutic nucleic acids encoding one or more proteins or enzymes related to cholesterol metabolism. In many cases, LNPs can deliver a variety of nucleic acids larger than those delivered by other methods. In some embodiments, the disclosed LNPs and / or LNP systems may include one or more of four components, variations of which can optimize their integrity and organ specificity, particularly for the liver. In some embodiments, LNP variants may include one or more of ionizable cationic lipids, phospholipids (typically phosphatidylcholine), cholesterol, and PEG lipids. Furthermore, some LNP formulations may include one or more molecules that facilitate targeting the LNP to specific cells or tissues.

[0070] Dosage

[0071] As used herein, the terms “dosage” or “prescription” refer to any form of active ingredient formulation in which the amount is sufficient to produce a therapeutic effect after a single application. In some embodiments, administration may also refer to the frequency at which a therapeutic dose is delivered to the patient.

[0072] The therapeutic compositions and methods disclosed in this invention can be administered in various forms, amounts, and frequencies. In some embodiments, the disclosed therapeutic dose can be from about 10 mg to about 0.01 mg per kilogram of patient body weight. In many embodiments, the dose is between about 5 mg and 0.1 mg / kg, for example, 0.25 mg / kg, 0.5 mg / kg, 0.75 mg / kg, 1.0 mg / kg, or 1.5 mg / kg. The frequency may vary depending on patient needs and delivery method, but in most embodiments, the frequency is from about once a month to twice daily. In one instance, the frequency may be twice a week.

[0073] Effective amount

[0074] With respect to the disclosed therapeutic compositions and methods, the phrase "effective amount" can refer to an amount of the disclosed composition or active ingredient sufficient to provide therapeutic, ameliorative, or preventive benefits in treating or preventing disease, or to delay, minimize, or alleviate one or more symptoms or conditions associated with the disease. Furthermore, with respect to the compositions of this disclosure, a therapeutically effective amount means an amount of therapeutic agent that provides therapeutic benefits in treating or preventing disease when used alone or in combination with other therapies. When used in conjunction with the therapeutic compositions and methods disclosed herein, the term can cover amounts or frequencies of administration that improve overall treatment, reduce or avoid disease symptoms, conditions, or causes, or enhance therapeutic efficacy or synergistic effects with other therapeutic agents.

[0075] The phrase "therapeuticly effective amount" means an amount of the disclosed compound that achieves the following: (i) treatment of the specific disease, ailment, or condition described herein; (ii) relief, improvement, or elimination of one or more symptoms of the specific disease, ailment, or condition; or (iii) prevention or delay of the onset of one or more symptoms of the specific disease, ailment, or condition. In the case of atherosclerosis or hypercholesterolemia, a therapeutically effective amount of the drug may reduce the size, volume, or area of ​​plaque, or affect the concentration of at least one component (e.g., collagen or lipids) in the plaque; inhibit (i.e., to some extent slow down, preferably stop) the growth of atherosclerotic plaques; or reduce the concentration of one or more lipids in the patient's serum or tissues. The efficacy of the drug may also be measured by assessing the duration of patient fatigue, depending on the extent to which it reduces the serum levels of one or more toxic or harmful compounds.

[0076] biomarkers

[0077] Biomarkers are objectively measurable and assessable characteristics that serve as indicators of normal biological processes, pathological processes, or pharmacological responses to therapeutic interventions. Biomarkers can be categorized into several types: predictive, prognostic, or pharmacodynamic (PD) biomarkers. Predictive biomarkers predict which patients are likely to respond to or benefit from a particular therapy. Prognostic biomarkers predict the likely course of a patient's disease and can guide treatment. Pharmacodynamic biomarkers confirm drug activity and help optimize dosage and administration regimens.

[0078] SRA1, or Steroid Receptor RNA Activator I, participates in regulating activities such as metabolism and adipogenesis by modulating (usually inhibiting) nuclear receptors and other factors. Increased SRA1 expression can have beneficial effects on macrophage function and reduce inflammation. Therefore, SRA1 expression, especially in the spleen, can be used to track treatment efficacy.

[0079] IL-10, or interleukin-10, is an anti-inflammatory cytokine that can block NF-κB activity, prevent myeloid cells from secreting IFNγ, and regulate the JAK-STAT signaling pathway. IL-10 also affects immune regulation, downregulating the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. IL-10 also affects B cell survival, proliferation, and antibody production.

[0080] Low-density lipoprotein (LDL) is a type of lipoprotein. Other types include very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL). When cells need to synthesize cholesterol, they absorb LDL through the LDL receptor (LDLR). The amount of LDLR on a cell is partly regulated by the protein PCSK9, which tags the LDL receptor for degradation. High LDL levels are associated with atherosclerosis.

[0081] Triglycerides are derived from glycerol and three fatty acids and are a major component of human fat. Hypertriglyceridemia is associated with lipid metabolism disorders such as hypercholesterolemia and cardiovascular disease.

[0082] Cholesterol is a lipid sterol that almost all animal cells can synthesize. Cholesterol synthesis is a complex and energy-intensive process that requires the coordinated action of more than fifteen enzymes. The cholesterol backbone consists of 27 carbon atoms, assembled by multiple enzymes, with all carbons derived from acetyl-CoA. The cholesterol ring cannot be opened in human cells through enzymatic action, meaning that the human body has difficulty lowering excess cholesterol levels.

[0083] Pregnenolone, formed by the cleavage of cholesterol side chains, has been shown to have anti-inflammatory effects on cell populations associated with atherosclerotic pathology. Pregnenolone is the first product of steroid synthesis in adrenal, ovarian, and testicular steroid-producing cells. In humans, it lacks progesterone, corticosteroid, estrogen, androgen, or anti-androgen activity. Human non-steroid-producing cells lack the enzymes to convert pregnenolone into downstream steroids; if these cells produce pregnenolone, it is readily secreted into the extracellular environment. Indeed, pregnenolone produced in vitro in non-steroid-producing cells (e.g., hepatocytes, monocytes / macrophages, fibroblasts, renal epithelial cells) using the disclosed compositions and methods is secreted into the extracellular medium, where it is readily detectable.

[0084] Treatment results

[0085] Plaque regression refers to a reduction in at least one measurable physical property of an atherosclerotic plaque. Physical properties may include, but are not limited to, surface area, volume, or height. In some embodiments, the disclosed therapy can cause a reduction of approximately 5% to 100%, such as approximately 70% to approximately 90%, and a reduction of more than approximately 30%, 40%, 50%, 60%, or more. For example, compared to pre-treatment measurements and / or to an untreated population, the disclosed therapeutic compositions and methods can reduce plaque volume in patients, where volume is based on imaging results from one or more invasive or non-invasive methods (e.g., intravascular ultrasound (IVUS), B-mode ultrasound, cardiac computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI)). In many implementations, the measured physical properties may be reduced by more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, and less than about 100%, 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, or 5%. In many implementations, the time interval for measuring reduction can be greater than approximately 1 month to approximately 24 months after treatment, for example, greater than approximately 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, and less than approximately 36 months, 30 months, 25 months, 24 months, 23 months, 22 months, 21 months, 20 months, 19 months, 18 months, 17 months, 16 months, 15 months, 14 months, 13 months, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 4 weeks, 3 weeks, or 2 weeks. In some implementations, for example, when a subject is assessed for a normalized plaque score, the average reduction in the normalized plaque score may exceed approximately 30%. In many cases, the normalized plaque score can be determined as a percentage of atherosclerotic volume, such as the percentage of luminal volume occupied by a single plaque. In many implementations, coronary computed tomography angiography (CCTA) can be used to determine the normalized plaque score.In many implementations, the mean reduction in normalized plaque score in the treated subject population (e.g., 2 or more subjects) may exceed about 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, and be less than about 100%, 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%, for example, about 42%.

[0086] The disclosed therapeutic compositions and methods can be used to alter the content of at least one component in atherosclerotic plaques. In most embodiments, the components of the disclosed compositions and methods can be lipids, and the treatment methods can reduce the lipid content in the atherosclerotic plaques of a subject. In most embodiments, the disclosed compositions and methods reduce lipid content in atherosclerotic plaques in subjects by more than 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 24%, 23%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, or 50%, and less than about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, or 5%. In many implementations, the time interval for measuring the reduction can be greater than approximately 1 month to approximately 24 months after treatment, for example, greater than approximately 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, and less than approximately 36 months, 30 months, 25 months, 24 months, 23 months, 22 months, 21 months, 20 months, 19 months, 18 months, 17 months, 16 months, 15 months, 14 months, 13 months, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 4 weeks, 3 weeks, or 2 weeks.

[0087] In some embodiments, the component is collagen. In embodiments where the component is collagen, the collagen content in the plaque may be increased. In many embodiments, the collagen content in the plaque may be increased to more than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, and less than about 100%, 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, or 5%. In many implementations, the time interval for measuring the increase can be greater than approximately 1 month to approximately 24 months after treatment, for example, greater than approximately 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, and less than approximately 36 months, 30 months, 25 months, 24 months, 23 months, 22 months, 21 months, 20 months, 19 months, 18 months, 17 months, 16 months, 15 months, 14 months, 13 months, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 4 weeks, 3 weeks, or 2 weeks.

[0088] The disclosed therapeutic compositions and methods can be used to alter the content or concentration of at least one serum component in a treated subject. In most embodiments, the disclosed serum component is selected from total cholesterol, free cholesterol, lipids, lipoproteins, triglycerides, cytokines, SRA1, IL-10, etc. In one embodiment, the disclosed therapeutic compositions and methods can reduce free cholesterol and / or triglycerides in the serum of a treated subject. In these implementations, the disclosed reductions may exceed about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, and be less than about 100%, 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, or 5%.

[0089] The disclosed therapeutic compositions and methods may have little effect on the concentration of low-density or very low-density lipoprotein in the serum of the treated subject. In these embodiments, the change in serum LDL and / or VLDL concentrations compared to the same subject before treatment may be less than about 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%, and may be greater than about 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, or 4%. In many embodiments, the time required for such change may be longer than about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 2 weeks, 3 weeks, or 4 weeks, and less than about 2 months, 4 weeks, 3 weeks, 2 weeks, 10 days, 9 days, 8 days, 7 days, 6 days, 5 days, 4 days, 3 days, or 2 days.

[0090] Indications / Diseases / Symptoms

[0091] The therapeutic compositions and methods disclosed in this invention can be used to treat or prevent a variety of diseases and conditions. In most embodiments, the diseases or conditions treated with the disclosed methods and compositions are related to hypercholesterolemia and / or atherosclerosis. In one embodiment, the disease or condition can be any form of atherosclerosis; while in many embodiments, the disclosed therapeutic compositions and methods can be used to treat genetic forms that accelerate atherosclerosis, such as familial hypercholesterolemia.

[0092] Autosomal homozygous familial hypercholesterolemia (FH) is a rare genetic disorder characterized by persistently elevated levels of low-density lipoprotein (LDL) cholesterol, leading to the rapid onset of coronary heart disease. Heterozygous FH (HeFH) is more common (1 in 200 to 1 in 500), affecting approximately 14 million to 34 million individuals worldwide. Individuals with heterozygous FH exhibit a clinical phenotype characterized by severely elevated plasma total cholesterol and LDL cholesterol levels, tendon xanthomas, and a high susceptibility to cardiovascular disease. Most familial hypercholesterolemias are hereditary conditions that disrupt normal lipid metabolism, typically caused by mutations in genes encoding the LDL receptor (LDLR), apolipoprotein B-100 (apoB), or proprotein convertase subtilisin / kexin type 9 (PCSK9). A defect in any of these genes that encode proteins essential for lipoprotein metabolism can lead to a significant increase in low-density lipoprotein cholesterol (LDL-C) levels.

[0093] Homozygous fibrillary hemorrhage (HoFH) is typically associated with the loss of LDL receptor expression or function. Although FH patients lack functional LDL receptors, uptake in macrophages still occurs via scavenger receptors (SRs), and the lack of LDL-Rs in other tissues leads to macrophages taking up more LDL. Therefore, FH patients have a higher risk of myocardial infarction or stroke, which typically occurs in the first two decades of life. Furthermore, these patients do not respond to lifestyle changes or statin therapy. Currently, the common treatment for homozygous FH relies on regular lipolysis. Homozygous FH is rare (approximately 1 in 1,000,000) and usually leads to late-stage CVD or death before age 20.

[0094] From a fundamental biochemical perspective, the increased risk of cardiovascular disease stems from the body's inability to remove excess cholesterol from the blood. Interestingly, several endogenous enzymes exist in human cells that may degrade intermediate metabolites produced after ring-opening. This suggests that ring-opening may be a missing step preventing the body from removing excess cholesterol and preventing its accumulation.

[0095] prevention

[0096] As used herein, “prevention” means the avoidance or recurrence of the disease, condition or ailment detailed herein by administering the compositions, compounds, treatments or therapies of this disclosure to a subject in need.

[0097] amino acids

[0098] Amino acids can be grouped according to the similarity of their side chain properties (see AL Lehninger, Biochemistry, 2nd edition, pp. 73-75, Worth Publishers, New York (1975)): (1) Nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) Uncharged, polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) Acidic: Asp (D), Glu (E); (4) Basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be categorized into the following groups based on common side-chain properties: (1) hydrophobic: leucine, Met, Ala, Val, Leu, Ile; (2) neutral-hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions would require replacing a member of one of these categories with one of the other. Specific conservative substitutions include, for example: Ala replaced with Gly or Ser; Arg replaced with Lys; Asn replaced with Gln or His; Asp replaced with Glu; Cys replaced with Ser; Gln replaced with Asn; Glu replaced with Asp; Gly replaced with Ala or Pro; His replaced with Asn or Gln; Ile replaced with Leu or Val; Leu replaced with Ile or Val; Lys replaced with Arg, Gln, or Glu; Met replaced with Leu, Tyr, or Ile; Phe replaced with Met, Leu, or Tyr; Ser replaced with Thr; Thr replaced with Ser; Trp replaced with Tyr; Tyr replaced with Trp; and / or Phe replaced with Val, Ile, or Leu.

[0099] The terms "amino acid identity," "residue identity," and "identity" used in this article refer to the structure of the functional group (R group) at a given position on the polypeptide backbone. Naturally occurring amino acid identities are (name / 3-letter code / single-letter code): alanine / ala / A; arginine / arg / R; asparagine / asn / N; aspartic acid / asp / D; cysteine / cys / C; glutamine / gln / Q; glutamic acid / glu / E; glycine / gly / G; histidine / his / H; isoleucine / ile / I; leucine / leu / L; lysine / lys / K; methionine / met / M; phenylalanine / phe / F; proline / pro / P; serine / ser / S; threonine / thr / T; tryptophan / trp / W; tyrosine / tyr / Y; and valine / val / V.

[0100] Amino acids in a molecule can be replaced to create engineered molecules or variants. Amino acid (aa or aa) residues can be replaced by residues with similar physicochemical properties, a process known as "conservative substitution"—for example, replacing one aliphatic residue with another (e.g., replacing each other with Ile, Val, Leu, or Ala), or replacing one polar residue with another (e.g., between Lys and Arg; between Glu and Asp; or between Gln and Asn). Other such conserved substitutions, such as those based on size, charge, polarity, hydrophobicity, chain rigidity / or orientation, etc., are well known in the field of protein engineering. Peptides containing conserved amino acid substitutions can be tested using any of the assays described herein to confirm whether the desired activity, such as binding, specificity, and / or function of the native or reference peptide, has been achieved.

[0101] While conserved substitutions within a protein (i.e., buried or solvent-inaccessible residues / sites) may alter protein structure or affect protein folding in some cases, conserved substitutions on or near the protein surface (i.e., exposed or solvent-accessible residues / sites) do not cause significant alterations to protein structure and / or function unless the altered surface protein is essential for interaction with another molecule, peptide, or protein. It is entirely possible for a skilled articulator to alter a disclosed protein sequence by introducing conserved substitutions at up to 20% of residues / sites without disrupting or changing the protein's structure and / or function.

[0102] The similarity between amino acid or peptide sequences can be expressed as homology between the two sequences, also known as sequence identity. Sequence identity is usually measured as a percentage of identity (the percentage of identical residues in a peptide or the percentage of identical bases in a nucleic acid; or similarity or homology); the higher the percentage, the more similar the two sequences are. Complete identity means that a given sequence is 100% identical in 50, 100, 150, or 200 bases or residues.

[0103] protein

[0104] As used herein, the terms “protein” and “peptide” are used interchangeably to refer to a series of amino acid residues linked together by peptide bonds between the α-amino and carboxyl groups of adjacent residues. The terms “protein” and “peptide” refer to polymers of amino acids, including modified amino acids (e.g., phosphorylated, glycosylated, etc.) and amino acid analogs, regardless of their size or function. While “protein” and “peptide” are generally used to refer to relatively large polypeptides, and the term “peptide” is generally used to refer to small polypeptides, there is overlap in the use of these terms in the art. In this document, the terms “protein” and “peptide” are used interchangeably when referring to gene products and fragments thereof. Therefore, exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the aforementioned substances.

[0105] Variants / Homologous

[0106] As used herein, "variant" refers to a polypeptide, nucleic acid, gene, sequence, or molecule that is substantially homologous to a naturally occurring or reference member but differs from the natural or reference member due to one or more deletions, insertions, substitutions, molecular structure, expression level, or other reasons. A variant polypeptide-encoded nucleic acid sequence encompasses a sequence that, compared to a natural or reference nucleic acid sequence, contains the addition, deletion, or substitution of one or more nucleotides, but encodes a variant protein or fragment thereof. Various cloning, PCR-based site-specific mutagenesis, and gene editing methods are known in the art and can be applied by those skilled in the art.

[0107] Any of a variety of techniques known to those skilled in the art can alter the natural amino acid sequence. For example, a mutation can be introduced at a specific site by synthesizing an oligonucleotide containing a mutated sequence and placing restriction sites on both sides of the mutated sequence to allow it to be linked to a natural sequence fragment. After linking, the resulting recombinant sequence encodes an analogue with the desired amino acid insertion, substitution, or deletion. Alternatively, a site-specific oligonucleotide mutagenesis procedure can be used to provide an altered nucleotide sequence having specific codons changed according to the desired substitution, deletion, or insertion. Techniques for performing such alterations are well-established and understood by those skilled in the art.

[0108] The variant amino acid or nucleic acid sequence may have at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher homology with the native or reference sequence. For example, the degree of homology (percentage of identity) between two sequences can be determined by comparing the native and variant sequences using free computer programs commonly available on the World Wide Web for this purpose (e.g., using the default settings of BLASTp or BLASTn). In many cases, evolutionarily conserved amino acids in a protein may not be modified in the published variant—for example, in the case of cytochrome P450, residues that interact with and retain heme, or sulfated amino acids located near the Fe group in the heme group. Conserved amino acids can be readily identified by those skilled in the art.

[0109] prevention

[0110] As used herein, “prevention” means the avoidance or recurrence of the disease, condition or ailment detailed herein by administering the compositions, compounds, treatments or therapies of this disclosure to a subject in need.

[0111] adjust

[0112] The term "modulate" or "modulation" refers to the ability of a compound to increase or decrease the function or activity of an organism, cell, protein, peptide, gene, biomarker, etc. ("target"). "Modulation" takes many forms and aims to encompass inhibition, antagonism, partial antagonism, activation, activation, and / or partial activation of target-related activity. Inhibitor compounds can bind to, partially or completely block stimulation, reduce, prevent, delay activation, inactivate, desensitize, or downregulate signal transduction. The ability of a compound to modulate target activity can be demonstrated in various ways, such as nucleic acid quantification (northern analysis), enzyme assays, or cell-based assays.

[0113] Subjects

[0114] Subjects, subjects in need, patients, and “people in need of treatment” include people with pre-existing conditions (such as hypercholesterolemia, for example, but not limited to atherosclerosis), as well as people at risk of or susceptible to the condition. These terms also include people receiving preventive or therapeutic treatments disclosed herein and other mammalian subjects.

[0115] treat

[0116] As used herein, “treatment” and “method of treatment” refer to the temporary or permanent, partial or complete elimination, reduction, suppression or improvement of clinical symptoms, manifestations or progression of events, diseases or ailments associated with the conditions and disorders described herein. As recognized in the relevant art, methods and medicines used as therapies can alleviate the severity of a given disease state, but it is not necessary to eliminate every manifestation of the disease to be considered useful. It is sufficient to merely reduce the effects of the disease (e.g., serum lipoprotein levels, plaque burden, etc., as disclosed herein) and / or reduce the number or severity of associated symptoms, or improve the effectiveness of other treatments, or produce other beneficial effects, or reduce the likelihood of the disease occurring or worsening in a subject. One embodiment of the disclosed therapeutic compositions and methods relates to a method for determining therapeutic efficacy, said method comprising administering a therapeutic treatment to a patient in an amount, duration and number of repetitions sufficient to induce sustained improvement relative to a baseline indicator reflecting the severity of a particular condition.

[0117] diagnosis

[0118] "Diagnosis" or "diagnostic" refers to determining the presence or nature of a disease or condition. Such testing methods can be used, for example, for the early diagnosis of diseases, determining whether a subject is susceptible to a certain disease or condition, monitoring the progression of a disease or condition or the progress of a treatment plan, assessing the severity of a disease or condition, predicting the outcome and / or recovery prospects of a disease or condition, or helping to determine the appropriate treatment for a subject.

[0119] Diseases / Diseases

[0120] This article discloses compositions and methods for treating various diseases, conditions and disorders that may be characterized by one or more symptoms, such as hypercholesterolemia, atherosclerotic heart disease, atherosclerosis, hyperlipidemia, coronary artery disease, etc.

[0121] Express

[0122] As used herein, “expression” refers to cellular processes involved in the production, display (e.g., on or at the cell surface / outer membrane) or secretion of RNA and proteins, including but not limited to transcription, transcript processing, translation, and protein folding, modification, and processing. Expression can refer to the transcription and stable accumulation of sense (e.g., mRNA) or antisense RNA derived from one or more nucleic acid fragments, and / or the translation of mRNA into polypeptides.

[0123] about

[0124] The terms “about” or “approximately” mean an acceptable error in a particular value as determined by a person skilled in the art, which will depend in part on how the value is measured or determined. In some embodiments, the terms “about” or “approximately” mean within 1, 2, 3, or 4 standard deviations. In some embodiments, the terms “about” or “approximately” mean within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05% of a given value or range. Whenever the term “about” or “approximately” appears before the first value in a sequence of two or more values, it should be understood that the term “about” or “approximately” applies to each value in that sequence.

[0125] Example

[0126] The applicant investigated the use of the disclosed LNP-mRNA CDP gene therapy to treat several mouse strains.

[0127] C57BL / 6 mice are typical inbred mouse strains, exhibiting highly consistent genetic characteristics or phenotypes. Therefore, this strain is often used to study the "typical" response to experimental treatments.

[0128] Example 1 - LNP-mRNA therapy delivered to liver tissue

[0129] REP-0003 is a liver-targeting LNP-mRNA therapy that binds to an N-acetylgalactosamine (GalNAc) ligand. GalNAc binds to the desialylate glycoprotein receptor ASGPR, which is highly expressed in hepatocytes of the liver. Therefore, the disclosed LNP-mRNA therapeutic compound targets hepatocytes. The active ingredient of REP-0003 is a fusion protein containing CDP1.

[0130] Example 2 - LNP - CDP Pharmacokinetics of mRNA in C57BL / 6 mice [RP277]

[0131] REP-0003 was administered intravenously to 4-week-old C57BL / 6J mice (Table 1). Mice were fed a GAN diet (40% fat, 20% fructose, 2% cholesterol, Research Diets: D09100310) for 6 weeks. Based on body weight, mice were divided into 7 study groups (AG; n=3 mice per group) and housed in metabolic cages. At the start of the study, the GAN diet was discontinued, and mice were fed a regular diet.

[0132] At the start of the study, mice received a single injection of PBS (Group A) or REP-0003 (Group BG) via the tail vein. Upon sacrifice (0–72 hours post-injection), mice were euthanized, and blood and organs (including the heart and aortic tree) were removed and frozen for future biochemical analysis or immediate histological processing.

[0133] Table 1

[0134] Total protein was extracted from the right hepatic lobe tissue of mice. Proteins were separated by SDS-PAGE, and the expression of CDP and tubulin was determined by Western blotting. CDP was quantified relative to the housekeeping protein α-tubulin.

[0135] like Figure 2 As shown, this study indicates that the half-life of the CDP protein is approximately 37.5 hours.

[0136] Example 3 - Using LNPs Targeting the Liver CDP mRNA gene therapy ApoE knockout mice

[0137] ApoE knockout Mice are deficient in apolipoprotein E, making them susceptible to atherosclerosis. ApoE- / - Mice. ApoE knockout The mice exhibited poor lipoprotein clearance and an accumulation of cholesterol ester-rich particles in their blood. These particles promote the formation of atherosclerotic plaques.

[0138] In these studies, sixty-four ApoE knockout Mice (4 weeks old, JAX002052) were fed a Western diet (0.2% cholesterol, Research Diets: D12079B) for 12 weeks and then randomly divided into 4 groups (G1-G4; Table 2).

[0139] This study was designed as a reversal study, so that all mice were switched to a low-fat control diet with corn starch added but no cholesterol added (Research Diets: D14042701).

[0140] Starting from day 0, LNP- was administered intravenously to mice over the next 6 weeks. null (G1, volume equivalent dose) or 1 mg / kg LNP- CDP mRNA qw (G3 and G4). In G2 and G4 ApoE knockout Mice were administered 5 mg / kg of atorvastatin daily via oral gavage (po).

[0141] Table 2

[0142] Six weeks after treatment, the mice were euthanized, and their blood and organs (including the heart and aortic tree) were removed and frozen for future biochemical analysis or immediate histological processing.

[0143] Serum and organ samples were measured to determine lipid plaque area, free cholesterol, triglycerides, LDL, VLDL, collagen, IL-10, and SRA1.

[0144] REP-0003 treatment significantly reduced the area of ​​atherosclerotic plaques, but did not lower serum LDL levels.

[0145] As shown in Figure 3, LNP- CDP mRNA treatment significantly reduced the area of ​​lipid plaques in the aortic root (left figure). However, serum LDL / VLDAL-cholesterol levels did not change compared to atorvastatin treatment. Specifically, compared to control mice (G1-LNP-empty), mice treated with REP-0003 (G3-LNP-) showed a significant reduction in lipid area. CDP mRNA showed a significant reduction in lipid area of ​​aortic root plaques. P=0.05 19%. In contrast, atorvastatin alone did not show a significant reduction.

[0146] Reduction of plaque lipids may help stabilize plaques, especially unstable ones. This stabilizing effect may reduce the risk of plaque rupture and subsequent cardiovascular events.

[0147] Although REP-0003 treatment did not alter serum LDL / VLDL levels, mice treated with atorvastatin alone showed a significant reduction in serum LDL / VLDL-cholesterol levels.

[0148] LNP-mRNA targeting the liver stabilizes distal plaques by increasing fibrosis and reducing plaque rupture and / or release. Risk

[0149] Figure 4The results showed that REP-0003 treatment significantly increased collagen content in atherosclerotic plaques at the aortic root of treated mice. Cholesterol-rich atherosclerotic plaques are unstable and may rupture, leading to plaque displacement. Such rupture and displacement often result in acute coronary events, such as myocardial infarction. Since collagen plays a crucial role in determining plaque stability, collagen content analysis was performed on aortic root plaques.

[0150] These studies demonstrate that REP-0003 treatment, in addition to significantly reducing plaque lipid content (as discussed above), also significantly increased plaque collagen content (P<0.05 compared to the mediator). In contrast, atorvastatin monotherapy had no effect on collagen content. REP-0003 monotherapy and combination therapy (atorvastatin + LNP-) CDP The mRNA increased collagen content to a similar degree, indicating that this response was specifically mediated by REP-0003 treatment.

[0151] Gene therapy targeting the liver reduces serum levels of free cholesterol and triglycerides.

[0152] like Figure 5 As shown, REP-0003 treatment reduced serum free cholesterol and triglyceride levels. While atorvastatin alone did not change serum free cholesterol and triglyceride levels in mice, REP-0003 treatment significantly reduced these markers compared to control mice. Combination therapy of atorvastatin and REP-0003 further reduced triglyceride levels without affecting free cholesterol levels.

[0153] Given that the target of REP-0003 treatment is intracellular free cholesterol, the applicant hypothesizes that REP-0003 treatment may reduce circulating free cholesterol. Lowering serum triglycerides is generally considered beneficial because there is evidence linking elevated triglyceride levels to atherosclerotic heart disease.

[0154] CDP treatment increases serum IL-10 levels

[0155] Because IL-10 has potent anti-inflammatory properties in macrophages and T cells, serum IL-10 levels were also measured. It is also known that IL-10 regulates many cellular processes that interfere with the formation and stability of atherosclerotic plaques.

[0156] Although atorvastatin alone has little effect on IL-10 levels (see...) Figure 6 However, REP-0003 treatment (with or without atorvastatin) significantly increased the level of IL-10 in the serum of the treated mice.

[0157] Not wanting to be limited by theory, the applicant hypothesizes that increased IL-10 expression may contribute to the observed effects of REP-0003 treatment on atherosclerotic plaques.

[0158] CDP treatment increases SRA1 expression in spleen tissue.

[0159] The spleen contains monocytes, which enter the circulation and migrate to areas of endothelial damage, such as atherosclerotic plaques. At the site of atherosclerotic plaques, splenic monocytes transform into macrophages.

[0160] Steroid receptor RNA activator I has been found to participate in the regulation of activities such as metabolism and adipogenesis by modulating (usually inhibiting) nuclear receptors and other factors. Increased SRA1 expression can have beneficial effects on macrophage function and reduce inflammation. Therefore, the applicant hypothesizes that REP-0003 treatment may affect SRA1 expression in the spleen.

[0161] Figure 7 The response to REP-0003 treatment showed elevated SRA1 expression in the spleen. This elevated expression was similar to that seen with atorvastatin treatment, and the combination of REP-0003 and atorvastatin appears to have a certain additive effect.

[0162] Low-dose gene therapy in ApoE knockout It can effectively treat atherosclerosis in mice.

[0163] The applicant investigated the administration of REP-0003. In these studies, the research... ApoE knockout Vascular plaque regression and liver lesions in mice responding to multiple doses of REP (with or without atorvastatin). 84 four-week-old mice. ApoE knockout Mice were fed a Western diet (0.2% cholesterol, Research Diets: D12079B) for 11 weeks and then randomly divided into 6 groups (A to F).

[0164] Table 3

[0165] Because this was a reversal study, all mice were switched to a normal diet, i.e., a low-fat control diet, on day 0, and were then administered intravenously with PBS (groups A and B, volume equivalent dose) or REP-0003 at doses thereof (groups C, D, and E; 0.25, 0.50, or 1.00 mg / kg of REP-0003, respectively) every 4 days (q4d) for the next 6 weeks.

[0166] Mice in groups B and F were administered 5 mg / kg atorvastatin orally by gavage daily (qd), while mice in the other groups (A, C, D, and E) were administered an equivalent volume of atorvastatin mediator by gavage.

[0167] Six weeks later, on day 41, after the last dose was administered, the mice were fasted for 6 hours and euthanized on days 42–44, and blood chemical / biomarkers, atherosclerotic plaques, and liver lesions were assessed.

[0168] These results indicate that when LNP- CDP At mRNA doses as low as 0.25 mg / kg, serum triglycerides decreased and serum IL-10 concentrations increased. These results are similar to those recorded in the studies described in Table 2, and at doses as low as 0.25 mg / kg, LNP- CDP mRNA also showed significant efficacy in reducing lipids in aortic root plaques and increasing plaque collagen composition.

[0169] Example 3- LDLR knockout Treatment of mice

[0170] LDLR (low-density lipoprotein receptor) knockout mice are a model for studying familial hypercholesterolemia (FH). Compared to normal mice, whose serum cholesterol levels are 80-100 mg / dL, LDLR knockout Mice on a typical diet showed elevated serum cholesterol levels of 200-400 mg / dL. On a high-fat diet, LDLR knockout The serum level in mice can exceed 2,000 mg / dL.

[0171] This study measured 4-week-old males LDLR knockout LNP- administered intravenously to mice CDP Pharmacokinetics of mRNA and its derived CDP protein and activity markers over 168 hours. Mice were fed a Western diet (0.2% cholesterol, Research Diets: D12079B) for 6 weeks. Mice were divided into 10 study groups (AJ; n=3 mice per group) based on body weight and housed in metabolic cages. Mice maintained the Western diet throughout the study.

[0172] At the start of the study, mice received either PBS (Group A) or 1.00 mg / kg LNP via tail vein. CDP A single injection of mRNA (BJ group). Mice were euthanized at sacrifice, and blood and organs (including the heart and aortic tree) were removed and frozen for future biochemical analysis or immediate histological processing.

[0173] Table 4

[0174] REP-0003 treatment can rapidly reduce serum lipids.

[0175] REP-0003 treatment LDLR knockout In mice, serum lipid levels showed a visible decrease. LDLR knockout The mice exhibited abnormal blood lipids and turbid serum. For example... Figure 8 As shown, after a single application of REP-0003, LDLR knockout Serum lipid levels in mice decreased significantly over time. (In the context of...) LDLR knockout Serum was prepared from mice at multiple time points up to 96 hours after a single administration of REP-0003.

[0176] Lowering serum triglycerides is generally considered beneficial because there is evidence that elevated triglyceride levels are associated with atherosclerotic heart disease.

[0177] Serum triglyceride levels were measured in mice treated with REP-0003. Although LDLR knockout The initial serum triglyceride levels in mice were much higher than ApoE knockout Mice, but as Figure 9 As shown, these studies indicate that REP-0003 treatment has... LDLR knockout The relative effect of serum triglyceride levels in mice on ApoE knockout The relative impact on mice was the same.

[0178] Figure 10 It was also shown that REP-0003 treatment could reduce LDLR knockout Serum total cholesterol in mice ( P<0.01 ).

[0179] Serum ALT levels decreased rapidly after REP-0003 treatment.

[0180] Elevated serum ALT levels are characteristic of liver disease. For example... Figure 11 As depicted, LDLR Knockout Mice had high SLT levels, but these levels decreased rapidly after REP-0003 treatment. Decreased serum ALT was associated with reduced hepatic cell stress and cell death.

[0181] REP-0003 treatment can reduce total cholesterol levels in liver tissue.

[0182] Excessive cholesterol in liver tissue is pathological, forcing cells to carry excessive amounts of toxic intracellular free cholesterol, leading to dysfunction.

[0183] like Figure 12As shown, after treatment with REP-0003, cholesterol levels in liver tissue were significantly reduced by day 3. P< 0.001 ).

[0184] REP-0003 mRNA therapy can rapidly reverse [the condition]. LDLR knockout Atherosclerosis in mice

[0185] This study aims to determine liver-specific delivery of LNP- CDP mRNA pairs LDLR knockout Effects of vascular plaque regression and liver lesions on mice. 78 four-week-old mice. LDLR knockout Mice were fed a Western diet (0.2% cholesterol, ResearchDiets: D12079B) for 16 weeks and then randomly assigned to 6 groups (A to F).

[0186] Because this was a reversal study, all mice were switched to a normal diet (low-fat control diet) on day 0 and administered PBS (group A, volume equivalent dose) or LNP at doses of 0.25, 0.50, 0.75, 1.00, and 1.50 mg / kg intravenously once weekly (qw) for the next 6 weeks. CDP mRNA (groups B to F). Six weeks later, after the last dose was administered on day 40, the mice were fasted for 6 hours and euthanized on days 41–44, and blood chemistry / biomarkers, atherosclerotic plaques, and liver lesions were assessed.

[0187] Table 5

[0188] In LDLR knockout mice treated with REP-0003, the size of aortic root plaques decreased rapidly.

[0189] Will LDLR Knockout mice were fed a high-fat Western diet for 16 weeks. Then, mice with existing plaques were switched to a low-fat control diet supplemented with corn starch but without added cholesterol (Research Diets: D14042701), and LNP was administered weekly. CDP mRNA, lasting for 6 weeks. Mice were divided into six groups, receiving either the vector or LNP- CDP mRNA, with a dosage range of 0.25 mg / kg to 1.50 mg / kg.

[0190] like Figure 13 As shown, mice treated with REP-0003 exhibited a significant reduction in aortic root plaque area compared to mice treated with the mediator. When averaged across all treatment groups, the treatment method of this invention resulted in a significant 17% reduction in plaque cross-sectional area relative to the aortic root cross-sectional area compared to the mediator control group.

[0191] Additional treatment can result in greater plaque regression.

[0192] At 0.25 mg / kg LDLR knockout Treatment in mice was sufficient to cause the plaques to disappear.

[0193] like Figure 14 As shown, although this study indicates that once-weekly administration of 0.25 mg / kg REP-0003 induces significant regression, increasing the dosing interval or concentration may provide additional benefits. Differences between groups were determined by the randomized distribution of treatment responsiveness.

[0194] Local variability in the severity of liver lesions LDLR knockout A characteristic of mice may be a factor determining the efficiency of the following: 1) LNP uptake by hepatocytes; 2) CDP Translation of mRNA; and 3) optimal cellular localization of CDP protein.

[0195] REP-0003 treatment also significantly improved treadmill exercise performance.

[0196] At the end of the study, for those who were sedentary... LDLR knockout The mice's endurance was assessed. The mice were made to run on a treadmill with a 10-degree incline and a maximum speed of 14 meters per minute. Time and distance were recorded when the mice stopped running for at least 10 seconds (indicating exhaustion).

[0197] Figure 15 The results showed that all groups receiving REP-0003 treatment were significantly better than those receiving mediator treatment, indicating improved cardiovascular function.

[0198] While several embodiments have been disclosed, other embodiments of the invention will become apparent to those skilled in the art from the following detailed description. As will be apparent, modifications can be made to the invention in various obvious aspects without departing from the scope and spirit of the invention. Therefore, the detailed description should be considered illustrative and non-limiting in nature.

[0199] All references disclosed herein, whether patent or non-patent, are incorporated herein by reference as if each reference were included in its entirety in the citation. In the event of any conflict between the references and the specification, this specification (including definitions) shall prevail.

[0200] While this disclosure has been described in detail to a certain extent, it should be understood that this disclosure is made by way of example and changes to details or structure may be made without departing from the spirit of this disclosure as defined in the appended claims.

Claims

1. A method for reducing at least one measurable aspect of atherosclerotic plaques in a subject, the method comprising: At least one atherosclerotic plaque in the subjects was identified by a measurement aspect having a first value; The composition is applied, the composition comprising: At least one cholesterol-degrading protein; At least one molecule or compound configured to bind to a protein on the surface of hepatocytes; and lipids; The at least one cholesterol-degrading protein is expressed in the hepatocytes; The measurement aspect is measured to determine a second value, wherein the difference between the first value and the second value is greater than 5%.

2. The method of claim 1, wherein the subject suffers from hypercholesterolemia.

3. The method of claim 1 or 2, wherein the subject suffers from familial hypercholesterolemia.

4. The method of claim 3, wherein the subject suffers from heterozygous familial hypercholesterolemia.

5. The method of claim 3, wherein the subject suffers from homozygous familial hypercholesterolemia.

6. The method of any one of claims 1-5, wherein the measurable aspect is selected from area, volume, and lipid or collagen content.

7. The method of any one of claims 1-6, further comprising the step of administering a statin or a PCSK9 inhibitor to the subject.

8. The method of any one of claims 1-7, wherein the cholesterol-degrading protein is a fusion protein.

9. The method of claim 8, wherein the fusion protein comprises cytochrome P450.

10. The method of claim 9, wherein the cytochrome P450 is type I or type II cytochrome P450.

11. The method of claim 10, wherein the type 1 cytochrome P450 is selected from CYP11 and CYP27.

12. The method of claim 11, wherein the type 1 cytochrome P450 is CYP11.

13. The method of claim 11, wherein the type 1 cytochrome P450 is CYP27.

14. The method of any one of claims 11-13, wherein the fusion protein comprises ferric reductase and ferric reductin.

15. The method of claim 14, wherein the fusion protein is CDP1 or CDP27.

16. The method of claim 10, wherein the cytochrome P450 is type 2.

17. The method of claim 16, wherein the type 2 cytochrome P450 is selected from CYP3, CYP7 and CYP8.

18. The method of claim 17, wherein the fusion protein comprises P450 reductase (POR).

19. The method of claim 17, wherein the fusion protein comprises P450 reductase (POR) and cytochrome b.

20. A composition for treating or preventing diseases associated with hypercholesterolemia, said composition comprising; At least one cholesterol degradation protein (CDP); Lipids encapsulating at least one CDP; And CDP; as well as Molecules or compounds configured to bind to proteins on the surface of hepatocytes.

21. A method for treating hyperlipidemia in a subject in need, the method comprising: The composition is administered to the subject, the composition comprising: At least one cholesterol degradation protein (CDP); Lipids encapsulating at least one CDP; And CDP; as well as Molecules or compounds configured to bind to proteins on the surface of hepatocytes; as well as The concentration of at least one serum biomarker affecting the subject.

22. The method of claim 21, wherein the biomarker is selected from total cholesterol, free cholesterol, lipids, lipoproteins, triglycerides, cytokines, SRA1, and IL-10.

23. The method of claim 21 or 22, wherein the biomarker is free cholesterol.

24. The method of claim 21 or 22, wherein the biomarker is triglycerides.

25. The method of claim 23 or 24, wherein the biomarker is reduced by more than 5% after administration.

26. The method of claim 21 or 22, wherein the biomarker is IL-10.

27. The method of claim 6, wherein the biomarker increases by more than 50% after administration.